Correction to Lancet Oncol 2021; 22: 581–83

Waissengrin B, Agbarya A, Safadi E, Padova H, Wolf I. Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors. Lancet Oncol 2021; 22: 581–83—In the fourth paragraph of this Comment, the IQR for the median number of days after the second vaccine dose should have been “(IQR 12–31)”, and the seventh paragraph should have read “Most patients (97 [72%] of 134) were treated with immune checkpoint inhibitors alone and 37 (28%) were treated with a combination of immune checkpoint inhibitors and chemotherapy. A similar rate of side-effects was observed in both treatment groups (31 [32%] of 97 vs 16 [43%] of 37; χ² p=0·22)”. And in paragraph ten, the number of patients who previously had grade 2 or worse immune checkpoint inhibitor-related side-effects should have been 47 (35%) of 134, and the third sentence should have read “There was no significant difference in the number of patients who reported systemic side-effects after the second dose of vaccine between those who had reported previous immune-related side-effects and those who had not (16 [34%] of 47 vs 30 [34%] of 87; p=0·96)”. These corrections have been made to the online version as of April 30, 2021.